Sildenafil To Prevent Clot (SToPClot)
Thrombosis, Hemolysis
About this trial
This is an interventional treatment trial for Thrombosis focused on measuring Thrombosis during Continuous Flow Pump Support
Eligibility Criteria
Inclusion:
-Adult outpatients (≥18 years old) with ongoing durable CF pump support.
Exclusion:
- Taking sildenafil or nitrates for clinical indications
- Ongoing infection
- Unwilling or unable to give written, informed consent
Sites / Locations
- Montefiore Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Sildenafil
Placebo Oral Tablet
Baseline blood samples and study measurements will be acquired. Then 20 mg of the study drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is < 5 mmHg after 2 hours and patient is asymptomatic), patient will proceed to take 20 mg of the study drug every 8 hours. The patient will return to clinic on day 8 and 20 mg of the study drug will be administered. After 2 hours blood samples and study measurements will be collected and the patient will resume 20 mg of the study for the next two doses. The patient will return for a third clinic visit on the next day and if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then the patient will continue taking 40 mg every 8 hours. The patient will return to clinic on day 15 for a final study visit and will be given the last 40 mg dose of the study drug and after 2 hours blood samples and study measurements will be taken.
Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.